Shattuck Labs Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Hi, my name is Alex. I work with Mark Breidenbach at Oppenheimer. Here joining me today is Taylor Schreiber. He's the CEO of Shattuck Labs.
Just a reminder for everyone, Shattuck is a clinical-stage company. They work on therapeutics that have both like agonists and inhibitor properties. Currently, their lead candidate SL-172154 is being studied in multiple indications of platinum-resistant ovarian, as well as MDS and AML. I would just give Dr. Schreiber here a chance to introduce himself.
Great. Thank you, Alex, and thank you to Oppenheimer for the invitation to present at this year's healthcare conference. As Alex said, I'm Taylor Schreiber, I'm the scientific founder and CEO of Shattuck Labs.
And what I'll be telling you about today is candidates from two different technology platforms that were developed within Shattuck, by Shattuck sciences. The first, which is where our lead clinical candidate was derived, is called the agonist
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |